Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
Merck Sharp & Dohme LLC
Aulos Bioscience, Inc.
Sotio Biotech Inc.
AstraZeneca
Neonc Technologies, Inc.
Replimune Inc.
Ariceum Therapeutics GmbH
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Regeneron Pharmaceuticals
Sotio Biotech Inc.
Transgene
NeoImmuneTech
Incyte Corporation
TuHURA Biosciences, Inc.
Fujifilm Pharmaceuticals U.S.A., Inc.
Memgen, Inc.
Pfizer
Sensei Biotherapeutics, Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
Checkpoint Therapeutics, Inc.
Vincerx Pharma, Inc.
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
ImmunityBio, Inc.
ImaginAb, Inc.
Arcus Biosciences, Inc.
4SC AG
ImmunityBio, Inc.
EMD Serono
Immunomic Therapeutics, Inc.
Philogen S.p.A.
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Power Life Sciences Inc.
OncoSec Medical Incorporated
Fate Therapeutics
Xencor, Inc.
Pfizer
Nektar Therapeutics
Kartos Therapeutics, Inc.
Incyte Corporation